Vanguard Group
VTYX

Vanguard Group’s Ventyx Biosciences VTYX Stock Holding History

Vanguard Group’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$35.6M Buy
3,943,566
+173,569
+5% +$1.3M ﹤0.01% 2351
2025
Q3 		$11.7M Buy
3,769,997
+607,725
+19% +$1.61M ﹤0.01% 2893
2025
Q2 		$6.77M Sell
3,162,272
-350,927
-10% -$567K ﹤0.01% 3099
2025
Q1 		$4.04M Buy
3,513,199
+5,112
+0.1% +$8.78K ﹤0.01% 3255
2024
Q4 		$7.68M Buy
3,508,087
+40,366
+1% +$91.5K ﹤0.01% 3083
2024
Q3 		$7.56M Buy
3,467,721
+473,479
+16% +$1.09M ﹤0.01% 3094
2024
Q2 		$6.92M Sell
2,994,242
-711,230
-19% -$2.96M ﹤0.01% 3106
2024
Q1 		$20.4M Sell
3,705,472
-36,453
-1% -$167K ﹤0.01% 2588
2023
Q4 		$9.24M Buy
3,741,925
+1,079,254
+41% +$10.2M ﹤0.01% 2986
2023
Q3 		$92.5M Buy
2,662,671
+277,906
+12% +$9.61M ﹤0.01% 1847
2023
Q2 		$78.2M Buy
2,384,765
+577,060
+32% +$19.9M ﹤0.01% 1988
2023
Q1 		$60.6M Buy
1,807,705
+311,534
+21% +$12.1M ﹤0.01% 2087
2022
Q4 		$49.1M Buy
1,496,171
+392,218
+36% +$11.6M ﹤0.01% 2198
2022
Q3 		$38.5M Buy
1,103,953
+197,014
+22% +$4.36M ﹤0.01% 2306
2022
Q2 		$11.1M Buy
906,939
+430,077
+90% +$6.43M ﹤0.01% 2941
2022
Q1 		$6.47M Sell
476,862
-91
-0% -$1.22K ﹤0.01% 3392
2021
Q4 		$9.47M Buy
+476,953
New +$9.04M ﹤0.01% 3239

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Vanguard Group's VTYX Position: Q4 2025 in Review

Vanguard Group increased its Ventyx Biosciences (VTYX) stake by 4.6% in Q4 2025, buying an estimated $1.3M and bringing the position to 3,943,566 shares worth $35.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

Vanguard Group first reported a position in VTYX in Q4 2021 and has held it in 17 quarters since. The position peaked at $92.5M in Q3 2023. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Vanguard Group held 3,943,566 shares of Ventyx Biosciences worth $35.6M as of Q4 2025.
  • Vanguard Group bought 173,569 Ventyx Biosciences shares in Q4 2025, an estimated $1.3M.
  • Ventyx Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2351 holding.
  • Vanguard Group first reported a position in Ventyx Biosciences in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Ventyx Biosciences position peaked at $92.5M in Q3 2023.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.